CA3124945A1 — Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
Assigned to Surface Ophthalmics Inc · Expires 2020-07-02 · 6y expired
What this patent protects
Pharmaceutical compositions are described, the compositions comprising an immunosuppressant (such as mycophenolic acid) in combination with a very low concentration of a corticosteroid (such as betamethasone) that are capable of treating, preventing, and/or alleviating an ocular …
USPTO Abstract
Pharmaceutical compositions are described, the compositions comprising an immunosuppressant (such as mycophenolic acid) in combination with a very low concentration of a corticosteroid (such as betamethasone) that are capable of treating, preventing, and/or alleviating an ocular surface disease. Methods for fabricating the compositions and using them are also described.
Drugs covered by this patent
- Temovate (CLOBETASOL PROPIONATE) · Fougera Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.